|Bid||241.28 x 800|
|Ask||250.28 x 800|
|Day's range||234.71 - 241.45|
|52-week range||212.40 - 317.17|
|Beta (5Y monthly)||1.04|
|PE ratio (TTM)||10.87|
|Earnings date||27 Jul 2022 - 01 Aug 2022|
|Forward dividend & yield||2.88 (1.20%)|
|Ex-dividend date||18 May 2022|
|1y target est||307.46|
BURLINGTON, N.C., June 28, 2022--Labcorp (NYSE: LH), a leading global life sciences company, today announced that it is enhancing its central laboratory presence and drug development capabilities in Japan through an expansion of CB Trial Laboratory, the central laboratory co-managed by Labcorp Drug Development and BML, a leading Japanese provider of clinical laboratory testing services.
BURLINGTON, N.C. & ALDIE, Va., June 24, 2022--Labcorp, a leading global life sciences company, and Tigerlily Foundation (Tigerlily), a leading breast cancer patient advocacy organization, today announced a new collaboration to increase clinical trial diversity for women of color and co-create health equity solutions. Labcorp has signed Tigerlily’s #InclusionPledge for Black Women, joining other healthcare and life sciences companies in committing to eradicate barriers for women of color in acces
According to LabCorp (LH), this partnership is expected to broaden its comprehensive, end-to-end drug development and clinical trial programs.